RxDoctor Payments Data

Tanya Marr

Family · Utica, NYNPI 1508205550

Payments from drug & device makers

$10,928in general payments, 2019–2025

Across 597 payments — averaging $18.31 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$958
  • Johnson & Johnson$718
  • E.r. Squibb & Sons, L.L.C.$656
  • AstraZeneca$632
  • Amgen$569
  • Daiichi Sankyo Inc.$536
  • plus $7K from 54 others

What the payments were for

  • Food & beverage$9,63888%
  • Education$1,29012%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Novartis67$958
Johnson & Johnson(2 entities)50$718
E.r. Squibb & Sons, L.L.C.49$656
AstraZeneca(2 entities)31$632
Amgen27$569
Daiichi Sankyo Inc.30$536
Merck21$407
Astellas Pharma US Inc13$382
Sanofi16$369
Pfizer19$361
Pharmacyclics LLC, An Abbvie Company20$361
Incyte Corporation11$327
Bristol Myers Squibb28$290
Takeda Pharmaceuticals U.S.A., Inc.13$288
Genentech USA, Inc.19$286
Lilly USA, LLC14$267
Sanofi-aventis U.S. LLC3$267
Regeneron Healthcare Solutions, Inc.12$257
Seagen Inc.6$252
ADC Therapeutics America, Inc.21$239
Myriad Genetic Laboratories, Inc.6$190
Epizyme, Inc.4$155
Eisai Inc.7$135
GSK6$110
Ipsen Biopharmaceuticals, Inc5$106
AbbVie6$104
Blueprint Medicines Corporation5$97
Aimmune Therapeutics, Inc.1$96
Array Biopharma Inc8$93
Gilead5$93
EMD Serono, Inc.4$82
Exelixis Inc.5$81
Karyopharm Therapeutics Inc.5$81
Kyowa Kirin, Inc.4$80
AVEO Pharmaceuticals, Inc.4$74
Genmab U.S., Inc.3$71
Azurity Pharmaceuticals, Inc.3$67
Bayer3$56
Pharmacosmos Therapeutics Inc.3$56
Taiho Oncology, Inc.4$55
Boehringer Ingelheim3$55
Puma Biotechnology, Inc.3$53
Mirati Therapeutics, Inc.2$47
Rigel Pharmaceuticals, Inc.3$44
G1 Therapeutics, Inc.3$41
Jazz Pharmaceuticals Inc.2$38
Coherus Oncology, Inc.2$38
Beigene USA, Inc.2$32
Morphosys, US Inc.2$31
Geron Corporation1$30
Argenx US, Inc.1$23
Stemline Therapeutics Inc.1$22
Apellis Pharmaceuticals, Inc.1$21
Tersera Therapeutics LLC1$20
Deciphera Pharmaceuticals Inc.1$18
CTI Biopharma Corp.1$17
Myovant Sciences Inc.1$16
Octapharma USA, Inc.1$15
Dendreon Pharmaceuticals LLC1$15
Sobi, Inc1$14

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$10,928 in reported general payments places this provider in the 95th percentile of 8,883 family providers in New York.

See all family providers in New York

Medicare billing

Part B allowed, 2024
$57,530
Medicare patients
338
Services billed
843

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Lenalidomide29$378,283
PomalystPomalidomide14$310,920
RevlimidLenalidomide15$253,315
VerzenioAbemaciclib15$223,805
VenclextaVenetoclax12$87,634
EliquisApixaban58$45,384
XareltoRivaroxaban31$26,228
Exemestane14$3,021
Anastrozole56$1,288
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen28$771
Potassium Chloride33$707
Hydroxyurea23$634
Levothyroxine Sodium58$583
Morphine Sulfate ErMorphine Sulfate12$511
Gabapentin47$480

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
E.r. Squibb & Sons, L.L.C.Pomalyst$656$310,92014 claims
Bristol Myers SquibbRevlimid$290$253,31515 claims
Lilly USA, LLCVerzenio$267$223,80515 claims
AbbVieVenclexta$104$87,63412 claims
PfizerEliquis$361$45,38458 claims
Johnson & JohnsonXarelto$718$26,22831 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 8,883 family providers in New York.

Other family in Utica

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →